U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07871747) titled 'Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)' on Oct. 07.
Brief Summary: Chimeric Antigen Receptor T-Cell (CAR-T) therapy has transformed the management of large B-cell lymphoma, and multiple myeloma by achieving remarkable responses, yet inconsistent durability and severe toxicities remain major challenges. To bridge this gap, this Phase 1 trial evaluates the safety and tolerability of a cGMP-compliant oral Live Biotherapeutic Product (LBP) consortium, selected for its capacity to produce butyrate, as an adjunct to standard Chimeric Antigen Receptor T-Cell CAR-T therapy, aiming to restore microbiome func...